Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests | Enterpreneurship
Guardant Health continued the rapid drumbeat of life science IPOs this year by raising $237.5 million in its stock market debut, making it one of the biggest IPOs so far this year.
The cancer diagnostics company priced its offering of 12.5 million shares at $19 apiece late Wednesday, well above the $15 to $17 per share range it had targeted. Shares of the Redwood City, CA, company are expected to begin trading on the Nasdaq later today under the stock symbol “GH.”
According to IPO research firm Renaissance Capital, the third quarter saw 52 companies raise $11.2 billion in capital… Read more »
UNDERWRITERS AND PARTNERS